Your session is about to expire
← Back to Search
Axitinib for Liver Cancer
Study Summary
This trial shows that for some types of cancer, a new immunotherapy drug can help to fight the disease even after the tumor has grown.
- Liver Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 13 Patients • NCT02129647Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many volunteers are participating in the research?
"Affirmative. Records on clinicaltrials.gov demonstrate that this research project, which was first published in November 4th 2022, is actively recruiting candidates. Approximately 29 individuals have to be enrolled from one medical clinic."
Has Axitinib been officially sanctioned by the FDA?
"Axitinib was assessed with a score of 2 on the safety scale due to Phase 2 trial data that suggests some safety, yet no evidence supporting efficacy."
Are volunteers still being accepted to participate in this investigation?
"Data hosted on clinicaltrials.gov supports the notion that this medical trial is recruiting volunteers as of November 4th 2022, which was also when the last edits to its information were made."
Share this study with friends
Copy Link
Messenger